Agreement will provide Lifespin with access to more than 25,000 longitudinal blood samples from approximately 4,800 oncological patients archived at Biobank Graz
Participating providers and laboratories get access to Lifespin’s proprietary software. With its scalability as Software-as-a-Service (SaaS) deep health data insights can be made available globally to participating organizations. The metabolic status of an individual is measured quantitatively with NMR and processed with Lifespin™ proprietary advanced artificial intelligence (AI) and deep learning algorithms for the determination of health status and diagnosis of diseases and results are delivered via the cloud (Illustration: Lifespin GmbH).
BOSTON–(BUSINESS WIRE)–Lifespin GmbH, based in Regensburg (Germany), with offices in Boston, Massachusetts, announced today that it has entered into a scientific collaborative agreement with Biobank Graz and the Clinical Division of Oncology of the Medical University of Graz (Austria) to expand its proprietary database of metabolic human health profiles in the field of oncology.
Under the agreement, Lifespin will be able to analyze and capture the metabolic profiles from more than 25,000 longitudinal human blood samples involving approximately 4,800 oncological patients. Terms of the agreement were not disclosed.
“We are excited about this very important partnership with the Medical University and with Biobank of Med Uni Graz, which we anticipate will be an aperture for further joint programs,” said Dr. Ali Tinazli, CEO of Lifespin GmbH. “The extraordinary depth of the data we will be able to analyze as a result of this important agreement will not only allow us to gain further insights to detect malignant diseases earlier, but will also provide valuable information on metabolic changes in cancer patients over time, notably to better understand individual treatment response and, post treatment and in remission, to improve patient monitoring and follow-up.”
Lifespin has already gathered a significant database of health profiles in oncology. “This substantial addition of about 25,000 longitudinal oncological patient samples to our already significant and proprietary database will enable us to further advance our algorithms to help clinicians detect diseases earlier, and more reliably customize treatment and monitoring options for patients using metabolomics as a valuable guide,” Tinazli added.
“Our scientific cooperation with Lifespin supports our central goal as physician scientists to apply translational cancer research towards clinical diagnostics and treatment implementations,” said Prof. Philipp Jost, Director of the Clinical Division of Oncology at the Medical University of Graz and member of the steering board of the Biobank Graz. “The Lifespin platform enables us to conduct metabolic analysis of samples from cancer patients at unprecedented depth and speed, providing a very important steppingstone for detecting cancer earlier and monitoring treatment responses more efficiently.”
Lifespin GmbH is a deep data company that is mapping the metabolic profiles of human health. The company is developing a groundbreaking, automated, highly scalable, and cost-effective next generation health diagnostics platform that utilizes artificial intelligence and machine learning to quantitatively identify variations in a person’s metabolism from the healthy baseline of relevant peer groups in its database. These variations can be linked to diseases with high sensitivity and specificity. Lifespin combines biology, deep data, artificial intelligence, and cloud technologies to enable digital metabolic insights for precision diagnostics and personalized disease management.
Earlier this year, to advance its research and development opportunities, and in preparation of its market entry, Lifespin GmbH announced the establishment of a U.S. subsidiary, Lifespin, Inc., based in Boston, Massachusetts.
Commercial products in the regulated space will be software algorithms for health testing, scalable via the cloud as Software-as-a-Service (SaaS). Development efforts are ongoing for a suite of products in the field of oncology to further extend Lifespin’s product portfolio over the coming years to be made available to participating providers and laboratories.
Contacts
Dr. Ali Tinazli, CEO, ali.tinazli@lifespin.health , +1 310-467-1112 and +49-160-257-3458
David Paine, Public Relations, PaineLab, david@painelab.com, +1 949-233-0050
